The Rise of RDCs: Market Momentum 

Radionuclide drug conjugates (RDCs) have rapidly transitioned from an emerging research concept to a clinically and commercially validated therapeutic modality. Over the past decade, increasing clinical adoption, regulatory approvals, and expanding development pipelines have positioned RDCs as one of the fastest-growing segments in targeted oncology therapeutics. Market projection estimate that the global RDC market will grow from approximately USD 3.24 billion in 2024 to nearly USD 8.87 billion by 2034, representing a compound annual growth rate (CAGR) of 10.54%. This momentum is driven by rising cancer incidence, increasing demand for precision medicine, and growing confidence in radiopharmaceutical technologies following multiple regulatory approvals.

Figure 1. Global Market Projection for RDCs and Radiopharmaceuticals (2024-2034)

From a clinical development perspective, RDCs have moved decisively beyond proof-of-concept and entered a phase of clinical execution. While the number of RDC programs has expanded rapidly over the past 5–8 years, this growth has been highly non-uniform. Despite substantial chemical diversity at the research level, most clinically successful RDCs converge on a limited set of targets, vector types, and radionuclide payloads—reflecting an emerging consensus around clinically viable RDC architectures shaped by safety, pharmacokinetics, manufacturability, and regulatory feasibility.

 

Approved RDCs: Clinical Validation

The clinical validation of RDCs is best illustrated by the growing number of regulatory approvals over the past two decades. Although radiopharmaceutical therapy has existed for many years, modern RDCs, defined by rational molecular targeting and well-controlled chelation chemistry, have only recently achieved broad commercial and clinical acceptance. These approved agents span both therapeutic radioligand therapies and diagnostic imaging agents, with several forming integrated theranostic pairs built on the same targeting ligand and chelation platform. Together, they illustrate how rational molecular design can be translated into standard clinical practice.

Table 1. Overview of Clinically Approved RDCs.

 

Across approved products, a clear architecture convergence emerges: validated surface targets (PSMA, SSTR2, CD20), small-molecule or peptides vectors, DOTA-based macrocyclic chelation, and β-emitters, particularly ¹⁷⁷Lu, form the backbone of clinical success. This pattern reflects practical clinical optimization rather than chemical constraint, emphasizing stability, manufacturability, predictable pharmacokinetics, and regulatory familiarity.

The parallel approval of diagnostic and therapeutic agents within the same target classes further highlights the defining strength of the RDC paradigm: imaging-guided patient selection and integrated dosimetry.

 

Case studies: Architectural Convergence

While the approved RDC landscape reveals clear structural convergence, examining representative products provides deeper insight into how these principles translate into clinical performance.

Case study 1. Lutathera®

Lutathera established peptide receptor radionuclide therapy (PRRT) as a standard treatment for somatostatin receptor-positive neuroendocrine tumors (NETs). Its success rests on three aligned elements:

·       Validated target biology: SSTR2 is highly expressed in well-differentiated NETs.

·       Theranostic workflow: ⁶⁸Ga-DOTATATE imaging enables patients selection prior to therapy.

·       Optimized radionuclide choice: ¹⁷⁷Lu provides a balanced half-life (6.7 days) and moderate β-penetration, suitable for disseminated lesions while maintaining manageable toxicity.

The clinical trial demonstrated significant progression-free survival benefits, solidifying Lutathera as proof that peptide-based targeting combined with DOTA-¹⁷⁷Lu chemistry can achieve durable clinical impact.

 

Case study 2. Pluvicto®

Pluvicto represents the commercial inflection point of modern radioligand therapy. By targeting PSMA with a small molecule inhibitor, this therapy expanded RDC success into metastatic castration-resistant prostate cancer (mCRPC).

Key architectural strengths include:

·       High-density, rapidly internalizing target (PSMA)

·       Small molecule vector enabling efficient tumor penetration.

·       DOTA-based chelation ensuring in vivo stability.

·       ¹⁷⁷Lu as a clinically validated β-emitter.

The clinical trial demonstrated significant overall survival improvement, transforming PSMA-directed radioligand therapy into a major oncology market segment.

Pluvicto further reinforced that small-molecule vectors paired with ¹⁷⁷Lu can achieve scalable manufacturing, regulatory approval, and broad clinical adoption.

Together, Lutathera and Pluvicto illustrate that successful RDCs arise from the alignment of validated biology, appropriate radionuclide physics, and stable chemical architecture.

Figure 2. Structural Comparison and Architectural Convergence: Lutathera® vs. Pluvicto®

 

Clinical Pattern: The Theranostic Model

The clinical success of modern RDCs follows a remarkably consistent pattern across indications and target classes. Unlike traditional oncology drugs, RDCs integrate diagnosis, patient selection, and therapy into a unified workflow. This theranostic model, imaging first then treat, has emerged one of the strongest predictors of both clinical efficacy and commercial viability.

Patients are typically screened using PET radiotracers such as ⁶⁸Ga or 18F. Only those demonstrating sufficient target expression proceed to therapeutic radionuclides such as ¹⁷⁷Lu. This imaging-guided selection improves response rates, reduces unnecessary radiation exposure, and enhance overall treatment efficacy.

A second defining pattern is the differentiated clinical positioning of β- and α-emitters. ¹⁷⁷Lu-based therapies have established themselves as the backbone of current practice due to their predictable safety profile and repeatable dosing cycles. In parallel, α-emitters (e.g., ²²⁵Ac, ²¹²Pb) are increasingly explored in settings where higher-precision cytotoxicity may be advantageous, including minimal residual disease and β-refractory tumors.

Finally, approved and late-stage RDC candidates consistently focus on targets that combine strong tumor expression with limited normal tissue uptake and compatibility with theranostic pairing, helping explain the repeated emergence of platforms such as PSMA and SSTR2, with expanding interest in targets like FAP and DLL3.

Together, these patterns suggest that RDC success is not accidental but follows reproducible clinical logic, one that integrates molecular imaging, controlled radiation delivery and biologically rational targeting.  

Figure 3. The Theranostic Workflow: The See-to-Treat Paradigm in RDC clinical Practice

 

Conclusion

As RDC development advances from clinical validation towards platform optimization, chemical architecture becomes increasingly critical. Chelation stability, linker design, hydrophobicity control, and manufacturability evolve from supporting elements to key enablers of clinical translation and long-term success.

At PrecisePEG, We support this design-driven stage of RDC development through integrated capabilities in chelator-linker engineering, conjugation chemistry, and radiopharmaceutical building blocks, helping translate molecular design principles into stable, scalable, and clinically viable radiopharmaceutical architectures.

 

References

1.     Maithania, H.; John, R.; Painoori, R.; Monpara, J.; Swaminathan, S.; Kalhapure, R. Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective. AAPS PharmSciTech 2026, 27, 117. https://doi.org/10.1208/s12249-026-03346-1

2.     Tran, H. H.; Yamaguchi, A.; Manning, H. C. Radiotheranostic landscape: A review of clinical and preclinical development. Eur. J. Nucl. Med. Mol. Imaging 2025, 52, 2685. https://doi.org/10.1007/s00259-025-07103-7

3.     Roesch, F.; Martin, M. Radiometal-theranostics: the first 20 years. J. Radioanal. Nucl. Chem. 2023, 332, 1557. https://doi.org/10.1007/s10967-022-08624-3

4.     Di Stasio, G. D.; Farulla, L. S. A.; Botta, F.; Gilardi, L.; Grana, C. M. Case study #4: Lutathera, a gold standard for peptide receptor radiopharmaceutical therapy. In Radiopharmaceutical Therapy; Bodei, L., Lewis, J. S., Zeglis, B. M., Eds.; Springer: Cham, Switzerland, 2023; pp 241–264. https://doi.org/10.1007/978-3-031-39005-0_14

5.     Zhang, S.; Wang, X.; Gao, X.; Chen, X.; Li, L.; Li, G.; Liu, C.; Miao, Y.; Wang, R.; Hu, K. Radiopharmaceuticals and their applications in medicine. Sig. Transduct. Target. Ther. 2025, 10, 1. https://doi.org/10.1038/s41392-024-02041-6